
 | Rituximab(¹³CD20¥Þ¥¦¥¹¡¦¥Ò¥È¥¥á¥é·¿¥â¥Î¥¯¥í¡¼¥Ê¥ë¹³ÂÎ) ¢¡ | 60-03 ¾ |
 |
 | Rituximab¤È¤·ì¼ðáç¡¡¡¦¡¦¡¦¼£ÎÅË¡¤Î¿ÊÊâ¡¡¡¡¡¡
¤Ï¤¸¤á¤Ë¡¡¡¡
µ.CD20¹³¸¶¡¡1.CD20¹³¸¶¤Ë¤Ä¤¤¤Æ¡¡2.R¡¦¡¦ ¢¡ | ʬ»ÒɸŪÌô ¾ |
 |
 | RituximabÎÅË¡¤Ë¤è¤êÈæ³ÓŪ°ÂÁ´¤ËÇò·ìɺÙ˦Áý¿¤ª¤è¤Ó·ì¾®ÈÄÍ¢·ì°Í¸¤ò¥³¥ó¥È¥í¡¼¥ë¤·ÆÀ¤¿Â¿ºÞÂÑÀB-CLL¤Î1Îã ¢¡ | Çò·ìÉ ¾ |
 |
 | RNAi¤Ë´Ø¤¹¤ë´ðÁø¦µæ¤È¤½¤Î±þÍÑ¡¡¡¦¡¦¡¦¤Ï¤¸¤á¤Ë¡¡¡¡
µ.RNAi¡¡1.RNAiȯ¸«¤Î·Ð°Þ¡¡2.RNAi¤ÎºîÍѵ¡½ø¡¡3.RNA¡¦¡¦ ¢¡ | ²½³ØÎÅË¡ ¾ |
 |
 | Salvage Chemotherapy¤È¤·¤Æ¤ÎUFT+CyclophosphamideÎÅË¡¤ÎÍÍÑÀ ¢¡ | Æý´â ¾ |
 |
 | ¢¡3920 | ¿©Æ»´â ¾ |
 |
 | Second-Line Chemotherapy¤È¤·¤Æ¤ÎWeekly Paclitaxel(Taxol)ÅêÍ¿¤¬Í¸ú¤Ç¤¢¤Ã¤¿º¬¼£ÅÙC¥¹¥¥ë¥¹°ß´â¤Î2Îã ¢¡ | ¥¹¥¥ë¥¹ ¾ |
 |
 | Second-Line¤È¤·¤ÆÅêÍ¿¤·¤¿Low-Dose CPT-11+5'-DFURÊ»ÍÑÎÅË¡¤¬Í¸ú¤Ç¤¢¤Ã¤¿Å¾°ÜºÆÈ¯Ä¾Ä²´â¤Î2Îã ¢¡ | ·ëIJ´â ¾ |
 |
 | Second-Line¼£ÎŤȤ·¤Æ¤ÎÊ´ËöCisplatinÀ½ºÞ´ÎưÃí¤¬¸ú²ÌŪ¤Ç¤¢¤Ã¤¿´ÎºÙ˦´â¤Î1Îã ¢¡ | ´Î¡´â ¾ |
 |
 | Self-Expandable Metallic StentαÃÖ¤¬ÍÍѤǤ¢¤Ã¤¿Á°ÄíÉô¶¹ºõ°ß´â¤ÎTS-1ÁÕ¸ú¾ÉÎã ¢¡ | °ß´â ¾ |
 |
 | Sentinel Node Navigation Surgery¤ÏÇÙ´â¼ê½Ñ¤Î¥ê¥ó¥ÑÀá³ÇÀ¶¤ò¤É¤³¤Þ¤Ç¾Êά¤Ç¤¤ë¤«? ¢¡ | ÇÙ´â ¾ |
 |
 | Sentinel node ¤ò¤á¤°¤ë²èÁü¿ÇÃǤο·µ»½Ñ | 59-01 |
 |
 | Sentinel node ¥È¥ì¡¼¥µ¡¼¤ÎÆÃÀ¤Ë´Ø¤¹¤ë¿·Ãθ«¡¡ ¢¡ | ¥»¥ó¥Á¥Í¥ë¥ê¥ó¥ÑÀá ¾ |
 |
 | Sister Mary Joseph's Nodule(ž°ÜÀçÁ´â)¤Î3¼«¸³Îã¤È¤ï¤¬¹ñ¤Ë¤ª¤±¤ëÊó¹ðÎ㤫¤é¤Îʸ¸¥Åª¹Í»¡ ¢¡ | ¤½¤Î¾¤Î´â ¾ |
 |
 | Skin-sparing mastectomy-ÆýÁ£MRI¤Î³èÍѤȼ굻¤Î¹©É×- ¢¡ | Æý´â ¾ |
 |
 | SMANCS¤Î´ÎưÃí¸å¤Ë°ßÀü¹¦¤òÍ褷¤¿1Îã¡ÝÉûº¸°ßư̮¤Î´ØÍ¿¤Ë¤Ä¤¤¤Æ¡Ý ¢¡ | ´Î¡´â ¾ |
 |
 | SNPs¾ðÊó¤ÈÉûºîÍÑ¡¡¡¦¡¦¡¦¥²¥Î¥à¾ðÊó¤È²½³ØÎÅË¡¡¡¡¡¹³¤¬¤óºÞÉûºîÍÑȯÀ¸¤Ë´Ø·¸¤¹¤ë°äÅÁ»Ò¿·¿¤Ë¤Ä¤¤¤Æ¡¦¡¦ ¢¡ | ¥²¥Î¥à ¾ |
 |
 | SNP²òÀϤˤè¤ëCommon Disease´ØÏ¢°äÅÁ»ÒñΥ ¢¡ | ²½³ØÎÅË¡ ¾ |
 |
 | StageIII,IV-A¹âÅٿʹԴκÙ˦´â¤ËÂФ¹¤ë´ÎÀÚ½ü¸åLow-DoseFPưÃíÎÅË¡¤ÎÀ®ÀÓ ¢¡ | ´Î¡´â ¾ |
 |
 | stageIVÂçIJ´â¤Ë¤ª¤±¤ëCimetidineÊ»ÍѲ½³ØÎÅË¡¤Î¸¡Æ¤ ¢¡ | ÂçIJ´â ¾ |
 |
 | StageIVç¹´â¤ËÂФ¹¤ëÊü¼ÍÀþ²½³ØÎÅË¡¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡ | Êü¼ÍÀþ´ØÏ¢ ¾ |
 |
 | STI571ÅêÍ¿¤Ë¤è¤ë½ÅÆÆ¤ÊÌô¿¾¤Î¤¿¤áÃæ»ß¤·¤¿¤¬¸·½Å¤Ê´Æ»ë²¼¤Ë¤ÆºÆÅêÍ¿¤¬²Äǽ¤È¤Ê¤êÁÕ¸ú¤òÆÀ¤¿Ä²´ÖËìgastro intestinal stromal tumor¡ÊGIST¡Ë¤Î1Îã ¢¡ | GIST ¾ |
 |
 | Sticktype¡¡CMC-Magnetite¤Ë¤è¤ëǾ¼ðá粹ǮÎÅË¡¤Î¸¡Æ¤ ¢¡ | 18-Supplement ¾ |
 |
 | Successful Management of a Patient with stage IIIA Non-Small Cell Lung Cancer Using Sensitivity-Based Induction Chemotherapy Report of a case ¢¡ | ÇÙ´â ¾ |
 |
 | Survivin-2B¥Ú¥×¥Á¥É¤Ë¤è¤ë´â¥Ú¥×¥Á¥É¥ï¥¯¥Á¥óÎÅË¡ ¢¡ | ÌȱÖÎÅË¡ ¾ |
 |
 | Survivin¤òɸŪ¤Ë¤·¤¿°äÅÁ»Ò¼£ÎŤδðÁÃŪ¸¦µæ ¢¡ | ÌȱÖÎÅË¡ ¾ |
 |
 | S¾õ·ëIJ´â½Ñ¸å¤Ë¶É½êºÆÈ¯¤«¤é·ëIJǴËì²¼¼ðáçÍÍ·ÁÂÖ¤òÄ褷¤¿ 1 Îã ¢¡ | £²·îÂ裲½µ¡§£±£±Æü¡Ê¶â¡Ë ¾ |
 |
 | S¾õ·ëIJ´â½Ñ¸å¤Î°Û»þÀ¸ÉΩÀç£Å¾°Ü¤Î1Îã¡¡¡¦¡¦¡¦¡¦¡¦ | 39-02 |
 |
 | S¾õ·ëIJ´âðôÉô¥ê¥ó¥ÑÀáºÆÈ¯¤ò¥³¥ó¥È¥í¡¼¥ë¤·Ä¹´üÀ¸Â¸¤¬ÆÀ¤é¤ì¤¿1Îã ¢¡ | ·ëIJ´â ¾ |
 |
 | T3(SE),T4(SI)¿Ê¹Ô°ß´â¤ËÂФ¹¤ëCDDP¾¯ÎÌÈ¿ÉüÊ¢¹ÐÆâͽËÉŪÅêÍ¿¤Î¸ú²Ì¤Ë¤Ä¤¤¤Æ ¢¡ | °ß´â ¾ |
 |
 | TAE ¸å Clostridium perfringens ÇÔ·ì¾É¤Ë¤è¤ëµÞ·ã¤ÊÍÏ·ì¤ò¤¤¿¤·¤Æ»àË´¤·¤¿Â¿È¯À¹ü¿ñ¼ð¹çÊ»´ÎºÙ˦´â¤Î1˶¸¡Îã ¢¡ | ¹ü¿ñ¼ð ¾ |
 |
 | TAEÄñ¹³À¤Î¿ȯ´ÎºÙ˦´â¤ËÂФ·¤Æ´Î±¦ÍÕÀÚ½ü½Ñ¸åĹ´üͽ¸å¤òÆÀ¤¿1Îã ¢¡ | ´Î¡´â ¾ |
 |
 | TamoxifenÅêÍ¿¤Ë¤è¤ê¹â¥È¥ê¥°¥ê¥»¥é¥¤¥É·ì¾É¤òÍ褷¤¿Æý´â½Ñ¸å¤Î3Îã ¢¡ | Æý´â ¾ |
 |
 | Taxane·Ï¹³¤¬¤óºÞ¤ª¤è¤Ótrastuzumab¤ÎÎ×¾²Æ³Æþ¤ÈÆý´â¤ÎÃæ¿õ¿À·Ðž°Ü¤Î¸¡Æ¤ ¢¡ | Æý´â ¾ |
 |
 | TaxaneÀ½ºÞ¤ò´Þ¤à½¸³ØÅª¼£ÎŤˤè¤ê²þÁ±¤Î¤ß¤é¤ì¤¿»ÒµÜÂδâÇÙž°Ü¤Î1Îã ¢¡ | »ÒµÜÂδâ ¾ |
 |
 | TaxaneÊ»ÍÑÊü¼ÍÀþÎÅË¡¤Ë¤è¤ê½ÅÆÆ¤Êͳ²»ö¾Ý¤òÍ褿¤·¤¿Æý´â¾ÉÎã¤Î¸¡Æ¤ ¢¡ | 8·îÂ裴½µ¡¡£²£¶Æü ¾ |
 |
 | Tegafur/Cisplatin/Isovorin¤Ë¤è¤ëChronomodulation Chemotherapy+CPT-11Ê»ÍѲ½³ØÎÅË¡¤¬ÁÕ¸ú¤·¤¿ÈóÀÚ½ü¡¦½Ñ¸åºÆÈ¯°ß´â¤Î3¾ÉÎã ¢¡ | °ß´â ¾ |
 |
 | Tegafur¡¤Cisplatin¡¤Isovorin¤Ë¤è¤ëChronomodulation Chemotherapy¤Ë¿·µ¬·Ð¸ý¹³´âºÞS-1¤òÉղ乤벽³ØÎÅË¡¤¬ÁÕ¸ú¤·¤¿¹âÎð¼Ô¿Ê¹Ô°ß´â¤Î2Îã ¢¡ | °ß´â ¾ |
 |
 | Temozolomide¤¬Í¸ú¤Ç¤¢¤Ã¤¿ºÆÈ¯Æý´â¿ñËìÇżð¤Î1Îã ¢¡ | 8·îÂ裴½µ¡¡£²£¶Æü ¾ |
 |
 | tetst¡¡¡¦¡¦¡¦¤ª¤ì¤ª¤ì¡¦¡¦ | Äɲ嫥ƥ´¥ê¡¼ |
 |
 | Th1/Th2¥Ð¥é¥ó¥¹¤ÈHCVÍÛÀ´Î¹ÅÊÑ´µ¼Ô¤Îȯ´â ¢¡ | ´Î±ê ¾ |
 |
 | Thalidomide,Celecoxib,Gemcitabine¤¬ÁÕ¸ú¤·¤¿ÀÚ½üÉÔǽ¿Ê¹Ôç¹´â¤Î1Îã ¢¡ | ç¹Â¡´â ¾ |
 |
 | Thalidomide,Celecoxib,Gemcitabine¤¬ÁÕ¸ú¤·¤¿ÀÚ½üÉÔǽÃÀǹ´â¤Î1Îã ¢¡ | ²½³ØÎÅË¡ ¾ |
 |
 | Thalidomide¡¤Celecoxib¡¤IrinotecanÊ»ÍÑÎÅË¡¤Ë¤è¤êÎɹ¥¤Ê·Ð²á¤ò¼¨¤·¤¿¿Ê¹Ôç¹´â¤Î1Îã ¢¡ | ²½³ØÎÅË¡ ¾ |
 |
 | Thalidomide¡¦Celecoxib¡¦Irinotecan¤ÈCDDP¶»¡¦Ê¢¹ÐÆâÅêÍ¿¤¬Ãø¸ú¤òÄ褷¤¿´âÀ¶»¿å¡¦Ê¢¿å¤Î2Îã ¢¡ | ´âÀÊ¢Ëì±ê ¾ |
 |
 | Thalidomide¡¦Celecoxib¡¦Vinorelbine¡¦CDDP¤¬ÁÕ¸ú¤·¤¿ÇżïÀÊ¢Ëì °ÀÃæÈé¼ð¤Î1Îã ¢¡ | ¤½¤Î¾¤Î´â ¾ |
 |
 | The 2nd Conference on Asian Trends in Prostate Cancer Hormone Therapy | 30-10 |
 |
 | Third Line¤ÇPaclitaxel WeeklyÅêÍ¿¤Ë¤è¤ê·Ð¸ýÀݼ褬²Äǽ¤È¤Ê¤Ã¤¿°ß´âÊ¢Ë잰ܤÎ1Îã ¢¡ | °ß´â ¾ |
 |
 | Third-Line¤È¤·¤ÆTS-1,CPT-11Ê»ÍѲ½³ØÎÅË¡¤ò»Ü¹Ô¤·Ä¹´üÀ¸Â¸¤¬ÆÀ¤é¤ì¤¿Krukenberg¼ðáç½Ñ¸å4·¿°ß´âºÆÈ¯À´âÀ¥ê¥ó¥Ñ´É¾É¤Î1¾ÉÎã ¢¡ | °ß´â ¾ |
 |
 | Third-Line¤È¤·¤Æ¤ÎCPT-11/CDDPÊ»ÍÑÎÅË¡¤Ë¤è¤ê°ß´â½Ñ¸å´âÀÊ¢Ëì±ê¤Ë¤è¤ëIJÊĺɤ¬²þÁ±¤·¤¿1¾ÉÎã ¢¡ | °ß´â ¾ |
 |
 | TIPS¤Ë¤è¤ê¼£ÎŤËÀ®¸ù¤·¤¿Æñ¼£À´ÎÀ¶»¿å¤Î1Îã ¢¡ | £¸·î£±Æü ¾ |
 |
 | TJÎÅË¡¤¬ÁÕ¸ù¤·¤¿ºÆÈ¯Æù¼ð¾ÉÎã¤Î2Îã¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡ | 9·îÂ裱½µ¡Ê1Æü¡Ë ¾ |
 |
 | TJÎÅË¡¤¬Ãø¸ú¤·¤¿»ÒµÜÂÎÉô´âÆù¼ð(VIb´ü)¤Î°ìÎã ¢¡ | 9·îÂ裱½µ¡Ê1Æü¡Ë ¾ |
 |
 | TLR4·ç»¥Þ¥¦¥¹¤Ë¤ª¤±¤ëTLR4ȯ¸½¼ù¾õºÙ˦¤ª¤è¤ÓOK-432³èÀÀ®Ê¬¼ðáçÆâÅêÍ¿¤Î¹³¼ðáç¸ú²Ì ¢¡ | ÌȱÖÎÅË¡ ¾ |
 |
 | Toremifene Citrate¹âÍÑÎÌÅêÍ¿¸å²¼»èÀÅÌ®·ìÀò¾É¤òÍ褷¤¿ºÆÈ¯Æý´â¤Î1Îã ¢¡ | Æý´â ¾ |
 |
 | ToremifeneÊ»ÍÑ/ÄãÎÌPaclitaxelÅêÍ¿¤¬ÁÕ¸ú¤·¤¿Æý´â¹ü¿ñ´â¾É¡¦´Îž°Ü¤Î1Îã ¢¡ | Æý´â ¾ |
 |
 | Trastuzumab(Herceptin(R)) ¢¡ | ʬ»ÒɸŪÌô ¾ |
 |
 | Trastuzumab(Herceptin(R))¤ÈÆý´â ¢¡ | ʬ»ÒɸŪÌô ¾ |
 |
 | Trastuzumab(Herceptin(R))¤ÎŬ±þ·èÄê¤ËFISHË¡¤Ï¤É¤³¤Þ¤ÇɬÍפ«? ¢¡ | ʬ»ÒɸŪÌô ¾ |
 |
 | Trastuzumab¤Èpaclitaxel¤Î½ÑÁ°²½³ØÎÅË¡¤Çpathological CR¤¬ÆÀ¤é¤ì¤¿anthracyclineÄñ¹³À¶É½ê¿Ê¹ÔÆý´â¤Î1¾ÉÎã ¢¡ | 8·îÂ裳¡Ý£²¡Ê£±£¸Æü¡Ë ¾ |
 |
 | Trastuzumab¤ÈPaclitaxelÊ»ÍÑÎÅË¡¤ÇCR¤¬ÆÀ¤é¤ì¤¿Å¾°ÜÀÆý´â¤Î1¾ÉÎã ¢¡ | Æý´â ¾ |
 |
 | TRiDAK (Tumor RNA-Introduced Dendritic Cell-Activated Killer)ºÙ˦¤ÎͶƳ ¢¡ | ÌȱÖÎÅË¡ ¾ |
 |
 | TS-1 ÄãÍÑÎÌ ½Ñ¸åÊä½õ²½³ØÎÅË¡¤¬Í¸ú¤È¹Í¤¨¤é¤ì¤¿CA19-9 »ºÀ¸°ß´â¤Î1Îã ¢¡ | £··îÂ裳½µ¡§£±£¶Æü¡ÊÅÚ¡Ë Â¾ |
 |
 | TS-1+Biweekly PaclitaxelÊ»ÍÑÎÅË¡¤¬ÁÕ¸ú¤·¤¿´âÀÊ¢¿å¡¦Ä¾Ä²¶¹ºõ¤òȼ¤¦ÀÚ½üÉÔǽ¿Ê¹Ô°ß´â¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | TS-1+CDDP¤¬Ãø¸ú¤ò¼¨¤·¤¿ÇÙÁ£´â¤Î1Îã ¢¡ | ÇÙ´â ¾ |
 |
 | TS-1+CDDP¤Ë¤è¤ë½ÑÁ°²½³ØÎÅË¡¤¬ÁÕ¸ú¤·¤¿Ê¢ÉôÂçÆ°Ì®¼þ°Ï¥ê¥ó¥ÑÀáž°ÜÍÛÀ°ßÁ£Ù¨Ê¿¾åÈé´â¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | ¢¡3923 | °ß´â ¾ |
 |
 | TS-1+CPT-11¡¡Ê»ÍÑÎÅË¡¤Ë¤è¤êCR¤òÆÀ¤¿ºÆÈ¯°ß´â¤Î1Îã ¢¡ | £··îÂ裵½µ¡§£³£±Æü¡ÊÆü¡Ë ¾ |
 |
 | TS-1+Low-Dose CDDP´ÎưÃí¤¬Í¸ú¤Ç¤¢¤Ã¤¿¿Ê¹Ô°ß´â¤È´ÎºÙ˦´â¤ÎƱ»þÀ½ÅÊ£¤Î1Îã ¢¡ | ´Î¡´â ¾ |
 |
 | TS-1+PaclitaxelÊ»ÍÑÎÅË¡¤Ë¤Æ´âÀÊ¢¿å¤¬¾Ã¼º¤·¤¿¥¹¥¥ë¥¹·¿°ß´â¤Î1Îã ¢¡ | ¥¹¥¥ë¥¹ ¾ |
 |
 | TS-1+PaclitaxelÊ»ÍÑÎÅË¡¤Ë¤Æ´âÀÊ¢¿å¤¬¾Ã¼º¤·¤¿°ß´â¤Î1Îã ¢¡ | ´âÀÊ¢Ëì±ê ¾ |
 |
 | TS-1,CPT-11Ê»ÍÑÎÅË¡¤¬ÁÕ¸ú¤·¤¿Ì¤Ê¬²½·¿ÂçIJ´â´Îž°Ü¾ÉÎã ¢¡ | ž°ÜÀ´Î¡´â ¾ |
 |
 | TS-1,DocetaxelÊ»ÍÑÎÅË¡¤Ë¤è¤êÎɹ¥¤ÊQOL¤ò°Ý»ý¤Ç¤¤¿Ê¢ËìÇżï¤òȼ¤¦ÈóÀÚ½ü°ß´â¤Î1¾ÉÎã ¢¡ | ´âÀÊ¢Ëì±ê ¾ |
 |
 | TS-1/CDDP¤ª¤è¤ÓTS-1/CDDPÊ»ÍÑÊü¼ÍÀþÎÅË¡¤Ë¤Æ´°Á´¾Ã¼º¤·¤¿Æ±»þÀ¿©Æ»°ß½ÅÊ£´â¤Î1Îã ¢¡ | ¿©Æ»´â ¾ |
 |
 | TS-1/CDDP½ÑÁ°²½³ØÎÅË¡¤¬ÁÕ¸ú¤·¸¶È¯Á㤬¾Ã¼º¤·¤¿¿Ê¹Ô°ß´â¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | TS-1/CDDP½ÑÁ°²½³ØÎÅË¡¤¬Ãø¸ú¤·¤¿¿Ê¹Ô°ß´â¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | TS-1/CDDP½ÑÁ°Êä½õ²½³ØÎÅË¡¤Ë¤è¤Ã¤Æ¸¶È¯Á㤬¾Ã¼º¤·¤¿¥¹¥¥ë¥¹°ß´â¤Î1Îã ¢¡ | ¥¹¥¥ë¥¹ ¾ |
 |
 | TS-1/CDDPʬ³äÅêÍ¿¤Ç¸¶È¯Á㤬CR¤È¤Ê¤Ã¤¿°ß´â´Îž°Ü¾ÉÎã¤Î1Îã ¢¡ | ž°ÜÀ´Î¡´â ¾ |
 |
 | TS-1/CDDPÊ»ÍѲ½³ØÎÅË¡¤¬ÁÕ¸ú¤·¤¿Â¿È¯À´Îž°Ü¤òȼ¤¦¿Ê¹Ô°ß´â¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | TS-1/CDDPÊ»ÍѲ½³ØÎÅË¡¤¬Ãø¸ú¤·¤¿Â¿È¯´Îž°Ü¤ò¤È¤â¤Ê¤¦AFP»ºÀ¸°ß´â¤Î1Îã ¢¡ | £±£°·î£±Æü£Õ£Ð ¾ |
 |
 | TS-1/CDDPÊ»ÍѲ½³ØÎÅË¡¤Ë¤Æ¼ê½Ñ²Äǽ¤È¤Ê¤êÉÂÍýÁÈ¿¥³Ø¾å´Îž°Ü¤¬´°Á´¤Ë¾Ã¼º¤·¤¿¿Ê¹Ô°ß´â¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | TS-1/CDDPÊ»ÍÑÊü¼ÍÀþÎÅË¡¤Ë¤Æ´°¼£¤·¤¿ðôÉô¡¦¶»Éô¾åÉô¿Ê¹Ô¿©Æ»´â¤Î1Îã ¢¡ | ¿©Æ»´â ¾ |
 |
 | TS-1/CDDPÊ»ÍÑÎÅË¡¤¬ÁÕ¸ú¤·¤¿´Îž°Ü¤òȼ¤¦¿Ê¹Ô°ß´â¤Î3Îã ¢¡ | ž°ÜÀ´Î¡´â ¾ |
 |
 | TS-1/CDDPÊ»ÍÑÎÅË¡¤¬ÁÕ¸ú¤·¤¿¿©Æ»´âºÆÈ¯¤Î1Îã ¢¡ | ¿©Æ»´â ¾ |
 |
 | TS-1/CDDPÊ»ÍÑÎÅË¡¤¬ÁÕ¸ú¤·¤¿Ê¢ÉôÂçÆ°Ì®¼þ°Ï¥ê¥ó¥ÑÀáž°ÜÍÛÀ°ß´â¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | TS-1/CDDPÊ»ÍÑÎÅË¡¤¬ÁÕ¸ú¤·º¬¼£ÅÙBŦ½Ð¼ê½Ñ¤¬²Äǽ¤È¤Ê¤Ã¤¿ÂçÆ°Ì®¼þ°Ï¥ê¥ó¥ÑÀáž°ÜÍÛÀ°ß´â¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | TS-1/CDDPÊ»ÍÑÎÅË¡¤¬Ãø¸ú¤·¤¿¹âÎð¼Ô¤ÓÌ¡¿»½á·¿°ß´â¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | TS-1/CDDPÊ»ÍÑÎÅË¡¤¬Ãø¸ú¤ò¼¨¤·¤¿ÂçIJ´â½Ñ¸å±ó³Öž°ÜºÆÈ¯¤Î1Îã ¢¡ | ÂçIJ´â ¾ |
 |
 | TS-1/CDDPÊ»ÍÑÎÅË¡¤Ë¤ÆCR¤¬ÆÀ¤é¤ì¤¿Bulky N2¤ª¤è¤ÓÂçÆ°Ì®¼þ°Ï¥ê¥ó¥ÑÀឰܤòȼ¤¦3·¿¥¹¥¥ë¥¹°ß´â¤Î1Îã ¢¡ | ¥¹¥¥ë¥¹ ¾ |
 |
 | TS-1/CDDPÊ»ÍÑÎÅË¡¤Ë¤Æ±ó³Öž°Ü¤¬¾Ã¼º¤·°ßÁ´Å¦½Ñ¤ò»Ü¹Ô¤·ÆÀ¤¿¿Ê¹Ô°ß´â¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | TS-1/CDDPÊ»ÍÑÎÅË¡¤Ë¤Æ¸¶È¯ÁãCR¤¬ÆÀ¤é¤ì¤¿´Îž°Ü¤òȼ¤¦°ß¾®ºÙ˦´â¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | TS-1/CDDPÊ»ÍÑÎÅË¡¤Ë¤Æ¼ê½Ñ¼£ÎŤò»Ü¹Ô¤·ÆÀ¤¿Ê¢ËìÇżï¤òȼ¤¦4·¿°ß´â¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | TS-1/CDDPÊ»ÍÑÎÅË¡¤Ë¤ÆÄ¹´üCR¤ò°Ý»ý¤·ÀÚ½ü¤Ë¤ÆÉÂÁã¾Ã¼º¤ò³Îǧ¤µ¤ì¤¿¿Ê¹Ô°ß´â¤Î1Îã | 39-01 |
 |
 | TS-1/CDDPÊ»ÍÑÎÅË¡¤Ë¤ÆÌçÌ®Æâ¼ðáçÀò¤¬¾Ã¼º¤·¤¿¿Ê¹Ô°ß´â¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | TS-1/CDDPÊ»ÍÑÎÅË¡¤Î͸úÀ¤ò¼¨º¶¤·¤¿¿Ê¹ÔºÆÈ¯°ß´â¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | TS-1/CDDPÊü¼ÍÀþÊ»ÍѲ½³ØÎÅË¡¤Ë¤è¤ê´°¼£¤·¤¿¿Ê¹Ô¿©Æ»´â¤Î1Îã ¢¡ | ¿©Æ»´â ¾ |
 |
 | TS-1/CDDPÎÅË¡¤¬ÁÕ¸ú¤·º¬¼£ÀÚ½ü¤¬²Äǽ¤È¤Ê¤Ã¤¿¿Ê¹Ô°ß´â¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | TS-1/CDDPÎÅË¡¤¬ÁÕ¸ú¤·ÂçÆ°Ì®¼þ°Ï¥ê¥ó¥ÑÀ᤬CR¤È¤Ê¤Ã¤¿¿Ê¹Ô°ß´â¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | TS-1/CDDPÎÅË¡¤¬Ãø¸ú¤·¤¿±ó³Öž°Ü¿©Æ»´â¤Î1Îã ¢¡ | ¿©Æ»´â ¾ |
 |
 | TS-1/CDDPÎÅË¡¤Ë¤Æ¼ê½Ñ²Äǽ¤È¤Ê¤Ã¤¿¿Ê¹Ô°ß´â¤Î1Îã ¢¡ | £··îÂ裵½µ¡§£³£±Æü¡ÊÆü¡Ë ¾ |
 |
 | TS-1/CDDPÎÅË¡¤Ë¤è¤Ã¤ÆÁÕ¸ú¡¦±äÌ¿¸ú²Ì¤¬ÆÀ¤é¤ì¤¿¹âÅٿʹԡ¦ºÆÈ¯°ß´â¤Î2¾ÉÎã ¢¡ | °ß´â ¾ |
 |
 | TS-1/Cisplatin(CDDP),DocetaxelÊ»ÍÑÎÅË¡¤Ë¤è¤êÎɹ¥¤ÊQOL¤ò°Ý»ý¤Ç¤¤¿Ê¢ËìÇżï¤òȼ¤¦ÈóÀÚ½ü°ß´â¤Î1Îã ¢¡ | ²½³ØÎÅË¡ ¾ |
 |
 | TS-1/Low-Dose CDDP¤Ë¤è¤ë½ÑÁ°²½³ØÎÅË¡¤¬Í¸ú¤Ç¤¢¤Ã¤¿¿Ê¹Ô°ß´â¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | TS-1/Low-Dose CDDPÊ»ÍÑÎÅË¡¤¬Í¸ú¤Ç¤¢¤Ã¤¿Â¿È¯¹üž°ÜºÆÈ¯°ß´â¤Î1Îã ¢¡ | ¹üž°Ü ¾ |
 |
 | TS-1/Low-Dose CDDPÎÅË¡¤¬Ãø¸ú¤·¤¿Ä¾Ä²´â¿ȯÇÙž°Ü¾ÉÎã ¢¡ | ·ëIJ´â ¾ |
 |
 | TS-1/MMC´ÎưÃíÎÅË¡,TS-1/CDDPÎÅË¡¤Ë²¹Ç®ÎÅË¡¤ò²Ã¤¨¤¿°ß´â´Îž°Ü¤Î1Îã ¢¡ | ²¹Ç®¼£Îо |
 |
 | TS-1/NedaplatinƱ»þÊ»ÍÑConcurrent Chemoradiotherapy¤ÎÎ×¾²ÂèIÁê»î¸³ ¢¡ | ²½³ØÎÅË¡ ¾ |
 |
 | TS-1/Paclitaxel(TXL)Ê»ÍÑÎÅË¡¤¬ÁÕ¸ú¤·¤¿ç¹¿»½á¤òȼ¤Ã¤¿¿Ê¹Ô°ß´â¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | TS-1/Weekly CDDPÊ»ÍѲ½³ØÊü¼ÍÀþÎÅË¡¤¬Ãø¸ú¤·¤¿¿Ê¹Ô¿©Æ»´â¤Î1Îã ¢¡ | ¿©Æ»´â ¾ |
 |
 | TS-1/Weekly CDDPÊ»ÍÑÎÅË¡¤Ë¤è¤êÇÙž°ÜÁ㤬¾Ã¼º¤·¤¿¿Ê¹ÔºÆÈ¯°ß´â¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | TS-1¡¦CDDPÊ»ÍÑÊü¼ÍÀþÎÅË¡¤¬ÁÕ¸ú¤·¤¿Barrett¿©Æ»´â¤Î1Îã ¢¡ | ¿©Æ»´â ¾ |
 |
 | TS-1¡¦CDDPÊ»ÍÑÊü¼ÍÀþÎÅË¡¤¬ÁÕ¸ú¤·¤¿´Î¹ÅÊѹçÊ»¿©Æ»°ßƱ»þÀ½ÅÊ£´â¤Î1Îã ¢¡ | ¿©Æ»´â ¾ |
 |
 | TS-1¡ÜCDDPÎÅË¡¤¬Ãø¸ú¤·¤¿Â¿È¯À¹üž°Ü¤ÈDIC¤ò¹çÊ»¤·¤¿°ß´â¤Î1Îã ¢¡ | DIC ¾ |
 |
 | TS-1¡ÜÄãÍÑÎÌCisplatin¤Ë¤è¤ë½ÑÁ°²½³ØÎÅË¡¤¬ÁÕ¸ú¤·,º¬¼£¼ê½Ñ¤¬²Äǽ¤Ç¤¢¤Ã¤¿ÂçÆ°Ì®¼þ°Ï¥ê¥ó¥ÑÀá¼ðÂç°ß´â¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | TS-1¤ª¤è¤ÓCDDP´ÎưÃí¤Ë¤è¤ë½Ñ¸å²½³ØÎÅË¡¤¬ÁÕ¸ú¤·¤¿Â¿È¯À´Îž°Ü¤òȼ¤¦¿Ê¹Ô°ß´â¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | TS-1¤¬ÁÕ¸ú¤·16¤«·îÅêÍ¿·Ñ³¤·¤Æ¤¤¤ë°ß´â¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | TS-1¤¬ÁÕ¸ú¤·¤¿4·¿StageIV¿Ê¹Ô°ß´â¤Î2Îã ¢¡ | °ß´â ¾ |
 |
 | TS-1¤¬ÁÕ¸ú¤·¤¿°ß´â½Ñ¸åÂçÆ°Ì®¼þ°Ï¥ê¥ó¥ÑÀឰܤÎ1Îã ¢¡ | °ß´â ¾ |
 |
 | TS-1¤¬ÁÕ¸ú¤·¤¿´Î¡¤¥ê¥ó¥ÑÀឰܤòȼ¤Ã¤¿ÀÚ½üÉÔǽ°ß´â¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | TS-1¤¬ÁÕ¸ú¤·¤¿¹üž°Ü¤ª¤è¤ÓÇżïÀ·ì´ÉÆâ¶Å¸Ç¾É¸õ·²¤òȼ¤Ã¤¿¿Ê¹Ô°ß´â¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | TS-1¤¬ÁÕ¸ú¤·Ä¹´üÀ¸Â¸¤¬ÆÀ¤é¤ì¤¿Ê¢ËìÇżï¤òȼ¤¦°ß´â¤Î2¾ÉÎã ¢¡ | °ß´â ¾ |
 |
 | TS-1¤¬Â¿È¯À´Îž°Ü¤ËÁÕ¸ú¤·¤¿¿Ê¹Ô°ß´â¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | TS-1¤¬Ãø¸ú¤·¤¿°ß´â½Ñ¸å´Îž°Ü¤Î1Îã¡¡¡¦¡¦¡¦¾ÉÎã¡¡
¡¡£·£¹ºÐ¡¡ÃËÀ¡¡Í©Ì禰ßÀÚ½ü
·Ð²á¡¡
¡¡¡¦¡¦ ¢¡ | °ß´â ¾ |
 |
 | TS-1¤¬Ãø¸ú¤·¤¿²¼°öƬ´âðôÉô¥ê¥ó¥ÑÀáºÆÈ¯Îã ¢¡ | °öƬ´â ¾ |
 |
 | TS-1¤¬Ãø¸ú¤·¤¿º¸º¿¹ü¾åãݤª¤è¤ÓÊ¢ÉôÂçÆ°Ì®¼þ°Ï¥ê¥ó¥ÑÀឰܤòȼ¤¦²£¹Ô·ëIJ´â¤Î1Îã ¢¡ | ·ëIJ´â ¾ |
 |
 | TS-1¤¬Ãø¸ú¤·¤¿Ãæ°öƬ¦ÊÉ·¿¿Ê¹Ô´â¾ÉÎã¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡ | °öƬ´â ¾ |
 |
 | TS-1¤¬Ãø¸ú¤·¤¿Æ¬ðôÉô´â¤Î2¾ÉÎã¡¡¡¦¡¦¡¦äÁ¹üƶ´â¡¡°öƬ´â¡¦¡¦ ¢¡ | ƬðôÉô ¾ |
 |
 | TS-1¤¬Í¸ú¤Ç¤¢¤Ã¤¿°ß´â¡¦ÇÙž°Ü¤Î1Îã¡¡¡¦¡¦¡¦¾ÉÎã
¡¡£µ£¶ºÐ¡¡ÃËÀ¡¡¥¢¥ë¥³¡¼¥ëÀ´Î¾ã³²¡¡ÅüǢɡ¦¡¦ ¢¡ | °ß´â ¾ |
 |
 | TS-1¤¬Í¸ú¤Ç¤¢¤Ã¤¿°ß´â´Îž°Ü¤Î1Îã¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡ | °ß´â ¾ |
 |
 | TS-1¤ÈBiweekly Paclitaxel(TXL)¤ÎÊ»ÍÑÎÅË¡¤¬Í¸ú¤Ç¤¢¤Ã¤¿¿Ê¹Ô°ß´â¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | TS-1¤ÈCDDP¤ÎÊ»ÍÑÎÅË¡¤¬ÁÕ¸ú¤·¤¿¿Ê¹ÔÃÀǹ´â¤Î1Îã ¢¡ | ÃÀÆ»´â ¾ |
 |
 | TS-1¤ÈCDDPÊ»ÍÑÎÅË¡¤¬Ãø¸ú¤òÁÕ¤·¤¿¹âÅٿʹ԰ߴâ¤Î2¾ÉÎã ¢¡ | °ß´â ¾ |
 |
 | TS-1¤ÈLow-Dose Cis-platinum¤Ë¤è¤ëÊ»ÍѲ½³ØÎÅË¡¤¬ÁÕ¸ú¤·¤¿°ß´âçÁž°Ü(Sister Mary Joseph's Nodule)¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | TS-1¤È¾¯ÎÌCDDPÊ»ÍѤ¬Í¸ú¤Ç¤¢¤Ã¤¿¿Ê¹ÔºÆÈ¯°ß´â¤Î3¾ÉÎã ¢¡ | °ß´â ¾ |
 |
 | TS-1¤È¾¯ÎÌCDDPÊ»ÍÑÎÅË¡¤¬ÁÕ¸ú¤·¤¿Â¿È¯´Îž°Ü¤òȼ¤¦½éȯ°ß´â¤Î4Îã ¢¡ | °ß´â ¾ |
 |
 | TS-1¤ÈÄãÍÑÎÌCisplatin¤Ë¤è¤ë¸ý¹Ð٨ʿ¾åÈé´â¤ËÂФ¹¤ë½ÑÁ°²½³ØÎÅË¡-Preliminary Study- ¢¡ | £··îÂ裴½µ¡§£²£´Æü¡ÊÆü¡Ë ¾ |
 |
 | TS-1¤ÈÊü¼ÍÀþ¾È¼ÍÊ»ÍѤ¬Ãø¸ú¤·¤¿¹¢Æ¬´â½Ñ¸åºÆÈ¯¤Î1Îã ¢¡ | ¹¢Æ¬´â ¾ |
 |
 | TS-1¤Ë¤ÆÊ¢¿å¤¬¾Ã¼º¤·¡¤º¬¼£ÅÙBÀÚ½ü½Ñ¤¬»Ü¹Ô²Äǽ¤È¤Ê¤Ã¤¿¿Ê¹Ô°ß´â¤Î1Îã ¢¡ | ´âÀÊ¢Ëì±ê ¾ |
 |
 | TS-1¤Ë¤è¤êCR¤ÎÆÀ¤é¤ì¤¿°ß´â½Ñ¸å¥ê¥ó¥ÑÀáºÆÈ¯¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | TS-1¤Ë¤è¤êCR¤ÎÆÀ¤é¤ì¤¿°ß´â½Ñ¸å¶É½êºÆÈ¯¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | TS-1¤Ë¤è¤êĹ´üÀ¸Â¸¤¬ÆÀ¤é¤ì¤¿ÂçÆ°Ì®¼þ°Ï¥ê¥ó¥ÑÀឰܰߴâ¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | TS-1¤Ë¤è¤ë½Ñ¸åÊä½õÎÅË¡Ãæ¤Ëȯ¾É¤·Weekly DocetaxelÎÅË¡¤Ë¤è¤êÃø¸ú¤ò¤ß¤¿°ß´âÊ¢ËìÇżï¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | TS-1¤Ë¤è¤ë½ÑÁ°²½³ØÎÅË¡¤¬ÁÕ¸ú¤·¤¿Bulky N2ž°Ü°ß´â¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | TS-1¤Ë¤è¤ë½ÑÁ°²½³ØÎÅË¡¤¬ÁÕ¸ú¤·ÀÚ½ü¤·ÆÀ¤¿¿Ê¹Ô°ß´â¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | TS-1¤Ë¤è¤ëÁ°¼£ÎÅÎò¤òͤ¹¤ë¿Ê¹Ô°ß´â´µ¼Ô¤ËÂФ¹¤ëPaclitaxel¤òÍѤ¤¤¿¼£Îŷи³ ¢¡ | °ß´â ¾ |
 |
 | TS-1¤Î·Ð°ßáñÅêÍ¿¤Ë¤ª¤±¤ëÌôʪưÂÖ¤ª¤è¤Óͳ²»ö¾Ý¤Î¸¡Æ¤ ¢¡ | ²½³ØÎÅË¡ ¾ |
 |
 | TS-1¤ÎÅêÍ¿¤Ç¾Ã¼º¤ò¤ß¤¿Àå٨ʿ¾åÈé´â¤Î1Îã ¢¡ | Àå´â ¾ |
 |
 | TS-1¤ÎÅêÍ¿¤Ë¤è¤ê¾Ã¼º¤·,Ĺ´üCR¤¬ÆÀ¤é¤ì¤¿Ãæ°öƬ٨ʿ¾åÈé´â¤Î1Îã ¢¡ | °öƬ´â ¾ |
 |
 | TS-1¤ò¥Ù¡¼¥¹¤È¤·¤¿CDDP,PTX¤Î·Ñ³ŪʻÍÑÎÅË¡¤¬ÁÕ¸ú¤·¤¿ÀÚ½üÉÔǽ¿Ê¹Ô°ß´â¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | TS-1¤ò´Þ¤à°ß´â¤Î¿ºÞÊ»ÍÑÎÅË¡ 1)°ß´â¤ËÂФ¹¤ëTS-1+CDDPÎÅË¡ ¢¡ | °ß´â ¾ |
 |
 | TS-1¤ò´Þ¤à°ß´â¤Î¿ºÞÊ»ÍÑÎÅË¡ 2)ºÆÈ¯¡¦¿Ê¹Ô°ß´â¤ËÂФ¹¤ëTS-1+ÄãÍÑÎÌCDDPÊ»ÍÑÎÅË¡ ¢¡ | °ß´â ¾ |
 |
 | TS-1¤ò´Þ¤à°ß´â¤Î¿ºÞÊ»ÍÑÎÅË¡ 3)TS-1 + Tailored CPT-11ÎÅË¡(JFMC31-0301)¤Î¥³¥ó¥»¥×¥È¤È¼ÂºÝ ¢¡ | °ß´â ¾ |
 |
 | TS-1¤ò´Þ¤àÊ»ÍÑÎÅË¡¡¡¡¦¡¦¡¦Æ¬ðôÉô´â¿ÇÎŤοÊÊâ¡¡¡¡Â¿ºÞÊ»ÍѲ½³ØÎÅË¡¡¦Êü¼ÍÀþ¼£ÎŤÎÊ»ÍѤθ¡Æ¤Êó¹ð¡¦¡¦ ¢¡ | Êü¼ÍÀþ´ØÏ¢ ¾ |
 |
 | TS-1¤òÃæ¿´¤Ë¿ºÞ¤òSequential¤ËÊ»ÍѤ·Ãø¸ú¤¬ÆÀ¤é¤ì¤¿°ß´â´Î¡¦ÇÙž°Ü¤Î1¾ÉÎã ¢¡ | ž°ÜÀ´Î¡´â ¾ |
 |
 | TS-1¤òÅêÍ¿¤·3ǯ2¤«·îÀ¸Â¸Ãæ¤ÎÊ¢Ë잰ܰߴâ¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | ¢¡3733 | ¹üž°Ü ¾ |
 |
 | TS-1³ÖÆüÅêÍ¿¤Ë¤è¤êĹ´üÀ¸Â¸Ãæ¤ÎÊ¢ËìÇżï¤òȼ¤¦4·¿°ß´â¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | TS-1¼£ÎŤËÄñ¹³À¤È¤Ê¤Ã¤¿¥ê¥ó¥ÑÀᤪ¤è¤ÓÉû¿Õž°ÜºÆÈ¯°ß´â¾ÉÎã¤ËÂФ·Paclitaxel¤ÎWeeklyÅêÍ¿¤ÇCR¤òÆÀ¤¿1Îã ¢¡ | °ß´â ¾ |
 |
 | TS-1¼£ÎÅÄñ¹³ÀºÆÈ¯°ß´â¤ËÂФ·TS-1+CPT-11Ê»ÍÑÎÅË¡¤¬Í¸ú¤Ç¤¢¤Ã¤¿1Îã ¢¡ | °ß´â ¾ |
 |
 | TS-1½ÑÁ°ÅêÍ¿¤Ë¤ÆCR¤òÆÀ¤¿Ê®ÌçÉô¿Ê¹Ô°ß´â¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | TS-1¾¯ÎÌÅêÍ¿¤Ë¤è¤êĹ´ü´ÖNC¤ò°Ý»ý¤·ÆÀ¤¿»Ä°ß´â¤Î1Îã ¢¡ | °ß´â ¾ |
 |